The FDA Center for Veterinary Medicine (CVM) sets the regulatory framework for animal health products in the world's largest market. Recent major actions include the BRAVECTO QUANTUM approval pathway (July 2025), NUMELVI approval (February 2026), Guidance for Industry #263 fully implementing veterinary oversight of medically important antimicrobials, and ongoing compounding rule revisions affecting telemedicine prescriptions. Generic entry pathways under MUMS (Minor Use Minor Species), Innovator Listing, and ANADA processes increasingly affect off-patent molecule pricing. This report analyzes FDA CVM approval timelines, regulatory strategy, and competitive implications.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• FDA CVM Approval Pathways — NADA, ANADA, MUMS, Conditional
• Recent Major FDA CVM Approvals 2024-2026
• Guidance for Industry #263 — Antimicrobial Veterinary Oversight
• Veterinary Compounding Rule Revisions and Telemedicine
• Generic Animal Health Product Entry — ANADA Process
• Veterinary Biologic Approval — USDA APHIS Coordination
• Pet Food Regulation — AAFCO and FDA CVM Roles
• FDA CVM Inspection and Manufacturing Standards
• Regulatory Strategy for Novel Therapeutics and Diagnostics
• Patent Cliff and Generic Entry Outlook 2026-2030
Table of Contents
1. Executive Summary
2. Market Overview
3. FDA CVM Approval Pathways
4. Recent Major Approvals
5. Guidance for Industry #263
6. Veterinary Compounding
7. Generic Entry Process
8. Veterinary Biologic Approval
9. Pet Food Regulation
10. Inspection and Manufacturing Standards
11. Regulatory Strategy
12. Patent Cliff Outlook
13. Market Challenges and Risks
14. Strategic Conclusions and Recommendations
15. Appendix
List of Tables
Table 1. FDA CVM Approval Pathway Timelines and Requirements
Table 2. Major FDA CVM Approvals 2024-2026
Table 3. Antimicrobial Veterinary Feed Directive Implementation
Table 4. Compounding Rule Revisions and Industry Impact
Table 5. ANADA Generic Approvals 2023-2026
Table 6. USDA APHIS Veterinary Biologic Approvals
Table 7. AAFCO Pet Food Regulation Updates
Table 8. FDA CVM Inspection Activity by Manufacturer
Table 9. Regulatory Strategy Comparison by Company
Table 10. Patent Cliff and Generic Entry Calendar 2026-2030
Companies Profiled
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Elanco Animal Health
Merck Animal Health
Phibro Animal Health
Vetoquinol
Virbac
Zoetis
